Characteristics Colon carcinomas | Â | MAP | Sporadic CRC | Sporadic MSI-high | Lynch (based on MMR mutations) |
---|---|---|---|---|---|
Average age at CRC |  | 49 years [CS] 59 years11 | 68 years | 67–75 years | 47 years |
TNM stage | III or IV | 34% (51/148) 55% (10/18)[1] | 42% (1781/4193) | 43% (19/44) | 15% (15/101) |
Proximal location | Â | 69% (35/51) [CS] 29% (7/24)11 43% (16/37)4 46% (6/13)31 | 23% (1887/8129) | 75% (308/411) | 67% (74/111) |
(Meta) synchronous CRC | Â | 23% (10/44) [CS] 33% (6/18)11 26% (8/29)4 | 2% (14/832) | Â | 18% (7/38) |
Poor Differentiation | Â | 26% (11/42) [CS] 22% (5/23)11 100% (16/16)31 | 10% (765/7590) | 41% (203/501) | 38% (38/101) |
Mucinous | (>50%) | 21% (9/42) [CS] 13% (3/23)11 0% (0/16)31 | 12% (292/2480) | 28% (104/376) | 35% (40/113) |
Crohn's like infiltrate | Conspicuous | 33% (13/40) [CS] 31% (5/16)31 | 28% (586/2059) | 54% (318/589) | 49% (37/76) |
Necrosis | Â | 40% (16/40) [CS] | 77% (356/465) | 17% (9/52) | Â |
TILs* | Present (moderate and marked) | 74% (31/42) [CS] 50% (8/16)31 | 24% (338/1406) | 58% (155/268) | 33% (4/12) |
 | Marked | 17% (7/42) [CS] | 4% (34/889) | 29% (63/218) | 17% (2/12) |
APC | Mutations ( †MCR, ‡ also outside the MCR) | 14% (5/36) [CS]†43% (6/14)11‡ 83% (5/6)31†| 63% (459/724)†* 52% (281/539)‡ | 5% (1/21)†41% (56/136)‡ | 33%(6/18)‡ |
KRAS | Mutations codon 12/13 | 64% (23/36) [CS] 64% (9/14)11 | 29% (1090/3710) | 20% (56/280) | 34% (91/267) |
Beta-catenin ( CTNNB1 ) | Nuclear staining | 11% (4/35) [CS] 71% (12/17)11 | 77% (138/179) | 13% (4/31) | 59% (40/68) |
 | Mutations | 0% (0/16)5 | 5% (30/610) | 7% (2/27) | 20% (11/56) |
P53 | Nuclear staining >25% | 34% (12/35) [CS] 53% (8/15)11 | 57% (668/1167) | 15% (20/130) | 72% (23/32) |
 | Mutations | 60% (9/15) [CS] 21% (3/14)11 | 43% (1808/4299) | 22% (21/95) | 22% (2/9) |
SMAD4 | Mutations | 26% (5/19) [CS] 0% (0/14)11 | 22% (17/77) | Â | 18% (2/11) |
MSI | High | 0% (0/33) [CS] 0% (0/17)11 18% (2/11)31 33% (1/3)43 | 12% (227/1834) | Â | 90% (88/98) |